Takeda in $62b deal to buy UK drugmaker

It marks the largest overseas acquisition by a Japanese company

Takeda Pharmaceutical agreed to buy Londonlisted Shire for £45.3 billion (Dh225.41 billion) yesterday, marking the biggest deal yet in a wave of transactions sweeping the drugs industry.

The acquisition — assuming it wins the backing of shareholders — will be the largest overseas purchase by a Japanese company and propel Takeda, led by Frenchman Christophe Weber, into the top 10 rankings of global drugmakers.

The tie-up crowns a hectic few months of M&A activity as big drugmakers look to improve their pipelines by bringing in promising medicines developed by younger companies.

The enlarged group will be a Japanese national champion in pharmaceuticals and a leader in gastroenterology, neuroscience, oncology, rare diseases and blood-derived therapies, used for serious conditions such as haemophilia.

The agreement came on the last day for Takeda to make a firm bid. Shire had rejected four previous offers, due to price concerns and the fact that the Japanese company is proposing to pay for much of the acquisition in stock.

The final deal is approximately 46 per cent cash and 54 per cent stock, leaving Shire shareholders owning around half of the combined group.

Shire investors will receive $30.33 (Dh111.40) in cash and either 0.839 new Takeda shares or 1.678 Takeda American depositary shares for each share, the companies said, valuing the offer at £48.17 a share based on the latest price and exchange rate.

That is a 60 per cent premium to the price before Takeda first declared its interest six weeks ago. “I think it is a good deal for Shire shareholders but not everybody may think that. However, the risk is that if shareholders vote this down then the shares are going to go down a lot,” said Polar Capital fund manager Dan Mahony.

The deal must get the support of 75 per cent of Shire’s voting shareholders. While some of them do not want to hold Takeda paper, Weber told reporters he believed investors would back the transaction. “Their board and our board is confident that both shareholders will see the benefit of the acquisition,” he said.

Analysts expected the shares to trade at a relatively wide discount, given investor unease over the large stock component and the fact that the deal is not expected to close until the first half of 2019.